You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK)擬設立新藥創新基金 首期募資規模超10億元人幣
阿思達克 10-17 09:52

復星醫藥(02196.HK)公布,與蘇州吳中經濟技術開發區管理委員會及蘇州市吳中金融控股集團簽訂《戰略合作框架協議》,就參與投資設立新藥創新基金等達成合作意向。

新藥創新基金擬由復星醫藥發起募集設立,首期募集資金規模約10億至15億元人民幣。

根據框架協議合作內容包括:新藥創新基金與其GP擬落地在吳中經開區;吳中經開區(通過引導基金)、吳中金控擬以有限合夥人身份參與投資新藥創新基金,合計出資額不超過新藥創新基金募資總規模的32%;新藥創新基金投資到落戶於吳中經開區的項目公司的總金額不低於人民幣3.2億元;吳中經開區同意為復星醫藥或其關聯方預留其生物醫藥產業園內的100畝土地,具體區域與價格將由雙方進一步商議,同時吳中經開區將為新藥創新基金及其落地項目提供各項優惠政策,包括但不限於場地、人才引進、稅收等。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account